Ipsen (IPN.PA) Announce a Sponsored Research Agreement With Harvard Medical School to Discover Novel Engineered Botulinum Toxins for Serious Neurologic Diseases
7/15/2013 10:43:27 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School (Harvard). Under the terms of the agreement, Ipsen will fund Harvard research for at least three years with the aim to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of serious neurologic diseases. The collaboration will combine Harvard’s discovery platform and botulinum toxins engineering expertise with Ipsen’s know-how in drug discovery and pharmaceutical R&D. Ipsen will have exclusive worldwide rights on any candidate recombinant toxin stemming from the collaboration. Ipsen will be responsible for the development and marketing of the new toxins and will make associated upfront, milestones and royalty payments to Harvard.
Help employers find you! Check out all the jobs and post your resume.
comments powered by